EGF-depleting vaccine plus nivolumab shows survival signal in advanced NSCLC
A phase II trial reports 11.9-month median overall survival with CIMAvax-EGF plus nivolumab in previously treated advanced NSCLC, with the ...
Tag: EGFR phosphorylation
POPULAR NEWS
-
Microbial Sources and Stress Shape the Hidden Endophytes of an Invasive Plant
-
Firebreaks Leave Lasting Scars in Grasslands While Wildfire Heals Fast
-
ZNF207 shields glutamine transporter ASCT2 from degradation to fuel liver cancer growth
-
Systematic review maps sustainability tensions in offshore wind development